Davunetide intranasal

Drug Profile

Davunetide intranasal

Alternative Names: AL-108; NAP; NAPVSIPQ

Latest Information Update: 16 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institutes of Health (USA); Tel Aviv University
  • Developer Allon Therapeutics
  • Class Antidementias; Eye disorder therapies; Neuropeptides; Neuroprotectants; Nootropics
  • Mechanism of Action Microtubule-associated protein modulators; Tau protein inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progressive supranuclear palsy
  • New Molecular Entity No
  • Available For Licensing Yes - Alzheimer's disease; Mild cognitive impairment; Schizophrenia

Highest Development Phases

  • Discontinued Alzheimer's disease; Mild cognitive impairment; Parkinson's disease; Progressive supranuclear palsy; Schizophrenia

Most Recent Events

  • 16 Jul 2013 Allon Therapeutics has been acquired by Paladin Labs
  • 18 Dec 2012 Efficacy data from a phase II/III clinical trial in Progressive supranuclear palsy released by Allon Therapeutics
  • 31 May 2012 Data Safety Monitoring Board recommends phase II/III trial in Progressive supranuclear palsy continue under existing protocol
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top